

Ultrasonic Enhancement of Gene Transfection in Murine Melanoma Tumors

Douglas L. Miller,^{*} Shiping Bao,⁺ Richard A. Gies⁺⁺ and Brian D. Thrall⁺⁺

^{*}Department of Radiology, University of Michigan, Ann Arbor, MI 48109-0553 USA

⁺US Transuranium and Uranium Registries, Washington State University, Richland, WA 99252 USA; ⁺⁺Battelle Pacific Northwest National Laboratory, P.O. Box 999, Richland, WA 99352 USA

(Received 2 March 1999; in final form 13 July 1999)

The enhancement of gene transfection by ultrasound (US) was evaluated *in vitro* using the B16 mouse melanoma model. Cultured cells were either exposed in suspensions *in vitro* or implanted subcutaneously in female C57BL/6 mice for 10-14 days and, subsequently exposed, *in vivo*. For comparison to results with a luciferase plasmid, a reporter plasmid for green fluorescent protein (GFP) was used to evaluate transfection efficiency. US was supplied by a system, similar to a Dornier HM-3 lithotripter, that produced shock waves (SW) of 24.4 MPa peak positive and 5.2 MPa peak negative pressure amplitudes at the focus. The plasmids were mixed with the suspension to achieve 20 $\mu\text{L mL}^{-1}$, or were injected intratumorally to provide 0.2 mg DNA per mL of tumor. Acoustic cavitation was promoted by retaining 0.2 mL of air in the 1.2-mL exposure chambers *in vitro* and by injecting air at 10 % of tumor volume *in vivo*. *In vitro*, cell counts declined to 5.3% of shams after 800 SW exposure, with 1.4% of the cells expressing GFP after 2 days of culture. *In vivo*, 2 days after 400 SW exposure, viable-cell recovery from excised tumors was reduced to 4.2% of shams and cell transfection was enhanced by a factor of about 8, reaching 2.5% of cell counts ($p < 0.005$ in *t*-test). These results show that strong tumor ablation induced by US shock wave treatment can be coupled with simultaneous enhancement of gene transfection. © 1999 World Federation for Ultrasound in Medicine & Biology.

USTUR-0142-99